MSCs for Prevention of MI-induced HF (PREVENT-TAHA)
Myocardial Infarction, Acute, Myocardial Infarction First, Myocardial Infarction, Anterior Wall
About this trial
This is an interventional treatment trial for Myocardial Infarction, Acute focused on measuring WJ-MSCs, Myocardial infarction, Heart failure, Regenerative medicine, Tissue therapy, Stem cell therapy
Eligibility Criteria
Inclusion Criteria:
- Age 18-65 years
- Either gender
- First myocardial infarction in the preceding 3 to 7 days
- Post-acute myocardial infarction left ventricular ejection fraction < 40%
- Negative pregnancy test (for women of reproductive age)
- Written informed consent
Exclusion Criteria:
- A history of any prior cardiac conditions (valvular, ischemic, or congenital disorders)
- Regional wall motion abnormalities outside the region of the infarction
- LV dysfunction due to other etiologies like non-ischemic cardiomyopathy, anthracycline use, or ethanol abuse (> 6 oz./day regularly)
- Poor echocardiography window
- Active infection, malignancy, or autoimmune disease
Sites / Locations
- Al-Zahra Heart Hospital, Shiraz University of Medical SciencesRecruiting
- Faghihi HospitalRecruiting
- Namazee HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Cohort 1
Cohort 2 (Control Group)
In the experimental group, 3-7 days after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive a single intracoronary infusion of 10^7 umbilical cord-derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) alongside conventional treatment.
In the control group, after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive only conventional treatment.